Immunotherapy era in the treatment of small cell lung cancer.
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Clinical Trials as Topic
/ methods
Humans
Immunologic Factors
/ administration & dosage
Immunotherapy
/ methods
Lung Neoplasms
/ immunology
Small Cell Lung Carcinoma
/ immunology
Treatment Outcome
Extensive stage
Immunotherapy
Limited stage
Small cell lung cancer
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
22 Jun 2021
22 Jun 2021
Historique:
received:
20
05
2021
accepted:
08
06
2021
entrez:
22
6
2021
pubmed:
23
6
2021
medline:
28
12
2021
Statut:
epublish
Résumé
Small cell lung cancer (SCLC) is differentiated from non-small cell lung cancers with its histological and morphological features, rapid response to chemotherapy, and recurrence in a short time after treatment is discontinued. Platinum plus etoposide chemotherapy combination has been used as a standard treatment, and no new drug has been found for more than 30 years in this disease. In research, the targeted pathways that may affect survival have not been identified yet. During the second half of the second decade of the 2000s, with immunotherapies that inhibit immune checkpoints, improvements in survival were achieved for the first time in treating SCLC after many years. Then a rapid increase was observed in chemotherapy plus immunotherapy combination studies in this field. Updated analyses of these studies were represented at international oncology meetings in 2020. Here, we reviewed immunotherapy studies conducted in patients with SCLC and the reflections on the daily practice.
Identifiants
pubmed: 34156575
doi: 10.1007/s12032-021-01535-5
pii: 10.1007/s12032-021-01535-5
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
86Références
World Health Organization. Globocan 2020; Cancer incidence and mortality statistics worldwide and by region. https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf .
Chan BA, Coward JIG. Chemotherapy advances in small-cell lung cancer. J Thorac Dis. 2013;5(S5):565–78.
Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, et al. ATLANTIS: a phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncol. 2019;15(3):231–9. https://doi.org/10.2217/fon-2018-0597 .
doi: 10.2217/fon-2018-0597
pubmed: 30362375
Paz-Ares L, Spigel D, Chen Y, et al. Initial efficacy and safety results of irinotecan liposome injection (NAL-IRI) in patients with small cell lung cancer. J Clin Oncol. 2019;37(15_Supp l):8562. https://doi.org/10.1200/JCO.2019.37.15_suppl.8562 .
doi: 10.1200/JCO.2019.37.15_suppl.8562
Yu G, Cai Q, Xu X, et al. Anlotinib-containing regimen for advanced small-cell lung cancer: a protocol of meta-analysis. PLoS ONE. 2021;16(3): e0247494. https://doi.org/10.1371/journal.pone.0247494 .
doi: 10.1371/journal.pone.0247494
pubmed: 33705427
pmcid: 7951826
Liu Y, Hu X, Jiang J, et al. A prospective study of apatinib in patients with extensive-stage small cell lung cancer after failure of two or more lines of chemotherapy. Oncologist. 2020;25(5):e833–42. https://doi.org/10.1634/theoncologist.2019-0391 .
doi: 10.1634/theoncologist.2019-0391
pubmed: 32250517
pmcid: 7216448
Owonikoko TK, Dahlberg SE, Sica GL, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol. 2019;37(3):222–9. https://doi.org/10.1200/JCO.18.00264 .
doi: 10.1200/JCO.18.00264
pubmed: 30523756
Blackhall F, Jao K, Greillier L, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study. J Thorac Oncol. 2021. https://doi.org/10.1016/j.jtho.2021.02.009 .
doi: 10.1016/j.jtho.2021.02.009
pubmed: 33607312
Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg. 2011;45(1):341–60.
doi: 10.1016/j.yasu.2011.04.003
Reck M, Heigener D, Reinmuth N. Immunotherapy for small-cell lung cancer: emerging evidence. Future Oncol. 2016;12(7):931–43. https://doi.org/10.2217/fon-2015-0012 .
doi: 10.2217/fon-2015-0012
pubmed: 26882955
Pavan A, Attili I, Pasello G, et al. Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges. J Immunother Cancer. 2019;7(1):205. https://doi.org/10.1186/s40425-019-0690-1 .
doi: 10.1186/s40425-019-0690-1
pubmed: 31383005
pmcid: 6683488
Galuppini F, Dal Pozzo CA, Deckert J, et al. Tumor mutation burden: from comprehensive mutational screening to the clinic. Cancer Cell Int. 2019;7(19):209. https://doi.org/10.1186/s12935-019-0929-4 .
doi: 10.1186/s12935-019-0929-4
Liu J, Zhou H, Zhang Y, Fang W, Yang Y, Hong S, Chen G, Zhao S, Chen X, Zhang Z, Xian W. Nomogram for patients with stage I small cell lung cancer: a competing risk analysis. Ann Oncol. 2019. https://doi.org/10.1093/annonc/mdz071 .
doi: 10.1093/annonc/mdz071
pubmed: 31959349
pmcid: 6771223
Peters S, Pujol J-L, Dafni U, et al. Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: results from the ETOP/IFCT 4–12 STIMULI trial. Ann Oncol. 2021:31(Suppl 4):S1211. https://doi.org/10.1016/j.annonc.2020.08.2326 .
doi: 10.1016/j.annonc.2020.08.2326
Ottensmeier C, Galea I, Cross N, et al. 1477P - A novel Phase II trial of ipilimumab, carboplatin and etoposide (ICE) for the first line treatment of extensive stage small cell lung cancer (SCLC). Ann Oncol. 2014:25(Suppl 4):iv516. https://doi.org/10.1093/annonc/mdu355.15
doi: 10.1093/annonc/mdu355.15
Lynch TJ, Bondarenko IN, Luft A, et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15_Supp 1):7531.
doi: 10.1200/JCO.2016.67.6601
Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740–8. https://doi.org/10.1200/JCO.2016.67.6601 .
doi: 10.1200/JCO.2016.67.6601
pubmed: 27458307
Horn L, Mansfield AS, Szczęsna A, IMpower133 Study Group, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9. https://doi.org/10.1056/NEJMoa1809064 .
doi: 10.1056/NEJMoa1809064
pubmed: 30280641
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–39. https://doi.org/10.1016/S0140-6736(19)32222-6 .
doi: 10.1016/S0140-6736(19)32222-6
pubmed: 31590988
Rudin CM, Awad MM, Navarro A, KEYNOTE-604 Investigators, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369–79. https://doi.org/10.1200/JCO.20.00793 .
doi: 10.1200/JCO.20.00793
pubmed: 32468956
Leal T, Wang Y, Afshin Dowlati A, et al. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. J Clin Oncol. 2020;38(15_Supp l):9000.
doi: 10.1200/JCO.2020.38.15_suppl.9000
Besse B, Menis J, Bironzo P, et al. LBA85 REACTION: a phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer. Ann Oncol. 2020;31(Suppl 4):S1211–S1212. https://doi.org/10.1016/j.annonc.2020.08.2327 .
doi: 10.1016/j.annonc.2020.08.2327
Camerini A, Banna GL, Cinieri S, et al. Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis. Clin Transl Oncol. 2019;21(6):790–5. https://doi.org/10.1007/s12094-018-1989-y .
doi: 10.1007/s12094-018-1989-y
pubmed: 30448956
Nie K, Guo X, You Y, et al. S-1 maintenance therapy in extensive stage small-cell lung cancer-a randomized clinical study. Cancer Control. 2020;27(2):1073274820932004. https://doi.org/10.1177/1073274820932004 .
doi: 10.1177/1073274820932004
pubmed: 32551853
pmcid: 7307401
Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). J Thorac Oncol. 2018;13(9):1393–9. https://doi.org/10.1016/j.jtho.2018.05.002 .
doi: 10.1016/j.jtho.2018.05.002
pubmed: 29775808
pmcid: 6833950
Ready N, Owonikoko TK, Postmus PE, et al. CheckMate 451: a randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after firstline platinum-based doublet chemotherapy (PT-DC). J Clin Oncol. 2016;34(15_Supp l):TPS8579.
doi: 10.1200/JCO.2016.34.15_suppl.TPS8579
Abughanimeh O, Ernani V, Marr A, Ganti AK. Current updates in management of relapsed/refractory small cell lung cancer. J Cancer Metastasis Treat. 2020;6:50. https://doi.org/10.20517/2394-4722.2020.110 .
doi: 10.20517/2394-4722.2020.110
NCCN Clinical Practice Guidelides in Oncology. Small cell lung cancer. Version 3. 2021.
Früh M, Ruysscher DD, Popat S, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):99–105. https://doi.org/10.1093/annonc/mdt178 .
doi: 10.1093/annonc/mdt178
Horita N, Yamamoto M, Sato T, et al. Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients. Sci Rep. 2015;5:15437. https://doi.org/10.1038/srep15437 .
doi: 10.1038/srep15437
pubmed: 26486755
pmcid: 4614251
Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–95. https://doi.org/10.1016/S1470-2045(16)30098-5 .
doi: 10.1016/S1470-2045(16)30098-5
pubmed: 27269741
Ready N, Farago AF, de Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: checkmate 032. J Thorac Oncol. 2019;14(2):237–44. https://doi.org/10.1016/j.jtho.2018.10.003 .
doi: 10.1016/j.jtho.2018.10.003
pubmed: 30316010
Horn L, Reck M, Gettinger SN, et al. CheckMate 331: an open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC). J Clin Oncol. 2016;34(15_Supp l):TPS8578.
doi: 10.1200/JCO.2017.35.15_suppl.TPS8578
Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol. 2017;35(34):3823–9. https://doi.org/10.1200/JCO.2017.72.5069 .
doi: 10.1200/JCO.2017.72.5069
pubmed: 28813164
Chung HC, Lopez-Martin JA, Chuan-Hao Kao S, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. J Clin Oncol. 2018;36(15_supp l):8506.
doi: 10.1200/JCO.2018.36.15_suppl.8506
Thomas A, Vilimas R, Trindade C, et al. Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study. J Thorac Oncol. 2019;14(8):1447–57. https://doi.org/10.1016/j.jtho.2019.04.026 .
doi: 10.1016/j.jtho.2019.04.026
pubmed: 31063862
pmcid: 6660419
Pawel JV, Vynnychenko I, Jiang H, et al. A phase II, open-label, multi-arm study of novel combinations of immunotherapies or DDR inhibitors in platinum-refractory, extensive disease small-cell lung cancer (ED-SCLC): BALTIC. J Clin Oncol. 2017;35(15_Supp l):TPS8585.
doi: 10.1200/JCO.2017.35.15_suppl.TPS8585